Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

May 24, 2016

Primary Completion Date

October 27, 2017

Study Completion Date

July 26, 2018

Conditions
Bacterial Infection
Interventions
DRUG

MBN-101

MBN-101 is a locally administered, anti-infective drug product

OTHER

Placebo

The placebo is comprised of the vehicle/excipients used to formulate MBN-101, but does not contain the active pharmaceutical ingredient

Trial Locations (6)

19104

University of Pennsylvania, Philadelphia

21215

LifeBridge Health, Inc., Baltimore

77030

The University of Texas - Health Science Center & Medical School at Houston, Houston

94110

Orthopedic Trauma Institute, University of California San Francisco, San Francisco

94143

UCSF - Parnassus, San Francisco

443215

OhioHealth Research Institute, Columbus

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University of Pennsylvania

OTHER

collaborator

University of California, San Francisco

OTHER

collaborator

Medpace, Inc.

INDUSTRY

collaborator

Congressionally Directed Medical Research Programs

FED

lead

Microbion Corporation

INDUSTRY